Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2022 Earnings Conference Call May 9, 2022 4:30 PM ET

Company Participants

Jennifer Viera - Director of IR & Corporate Communications

Jay Luly - President and CEO

Paul Mellett - CFO

Nathalie Adda - Consultant

Tara Kieffer - SVP, New Product Strategy & Development

Conference Call Participants

Luke Herrmann - Robert W. Baird

Brian Abrahams - RBC Capital Markets

Swapnil Malekar - Piper Sandler

Akash Tewari - Jefferies

Roy Buchanan - JMP Securities

Hannah Adeoye - JPMorgan

Jay Olson - Oppenheimer

Zegbeh Jallah - ROTH Capital Partners

Roanna Ruiz - SVB Leerink

Operator

Good afternoon. And welcome to Enanta Pharmaceuticals' Fiscal Second Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session at the end of the prepared remarks. Please be advised that this call is being recorded.

I would now like to turn the call over to Jennifer Viera, Investor Relations. Please go ahead. .

Jennifer Viera

Thank you, operator, and thanks to everyone for joining us this afternoon. The news release with our fiscal second quarter 2022 financial results was issued this afternoon and is available on our website. On the call today are Dr. Jay Luly, President and Chief Executive Officer; Paul Mellett, our Chief Financial Officer; and other members of Enanta's senior management team.

Before we begin with our formal remarks, we want to remind you that we will be making forward-looking statements, which may include our plans and expectations with respect to our research and development pipeline and financial projections, all of which involve certain assumptions and risks beyond our control that could cause our actual developments and results to differ materially from those statements.

A description of these risks is in our most recent Form 10-Q and other periodic reports filed with the SEC. Enanta does not undertake any obligation to update any forward-looking statements made during this call.

With that, I'd now like to turn the call over to Dr. Jay Luly, President and CEO. Jay?

Jay Luly

Thank you, Jennifer, and good afternoon, everyone. Last quarter was an important one for Enanta during which we made progress in our pipeline and advanced our mission of developing therapeutics for life-threatening viral infections. This progress comes at an important time as we are soon approaching meaningful inflection points in our pipeline.

Today, I'll start by detailing our most advanced programs in respiratory virology where we continue to build an industry-leading treatment portfolio. Respiratory syncytial virus, or RSV, can result in a severe respiratory infection and is associated with significant morbidity and mortality. The virus can cause serious disease in children, the elderly and the immune compromise, and there are no targeted treatments or vaccines available.